Skip to main content

Table 6 OS according to baseline serum levels and CEA, CYFRA and NSE reduction ≥ 20%

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

 

Mean OS (95% CI)a (months)

p-value

Baseline CEA

< 5

12.2 (8.1–16.0)

0.035

≥ 5

5.6 (2.9–8.2)

Baseline CYFRA21-1

< 3.3

13.2 (11.0–14.3)

0.005

≥ 3.3

5.6 (3.4–7.7)

Baseline NSE

< 13.4

10.0 (6.2–13.7)

0.028

≥ 13.4

2.2 (0.2–5.0)

CEA reduction ≥ 20% a

No

9.9 (8.5–11.3)

0.026

Yes

15.0 (12.7–17.3)

CYFRA21-1 reduction ≥ 20% a

No

10.0 (8.4–11.6)

0.019

Yes

14.6 (12.4–16.8)

NSE reduction ≥ 20% a

No

11.6 (9.9–13.4)

0.950

Yes

12.4 (9.8–15.0)

  1. aMedian survival not reached